Fournier’s Gangrene Lawsuit Settlement Amounts 2026

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

Fournier’s gangrene lawsuit settlement amounts in 2026 range from an estimated $100,000 to over $2 million per case, depending on injury severity. These cases target makers of SGLT2 inhibitor diabetes drugs linked to this rare, life-threatening genital infection.

If you or a family member developed Fournier’s gangrene after taking Invokana, Farxiga, Jardiance, or Steglatro, you may have a valid legal claim. The FDA flagged this risk back in 2018, and drug makers still face accusations of failing to warn patients.

This article covers the latest settlement projections, who qualifies, how payouts are calculated, drug-specific case updates, and exactly how to file. One detail that catches most people off guard: fewer than 100 confirmed cases were reported to the FDA before the warning, yet the actual number of affected patients is believed to be far higher.

You might also find this useful — Young Durham Real Estate Lawsuit 2026: Full Claim Guide

Stick with this guide to get every answer you need for 2026.

Fournier’s Gangrene Lawsuit Settlement Amounts

Fournier’s gangrene lawsuit settlement amounts vary widely based on the severity of injury, number of surgeries required, and long-term medical consequences. Most legal analysts project individual settlements falling between $100,000 and $2 million or more for qualifying cases in 2026.

These are not small-dollar consumer claims. Fournier’s gangrene is a flesh-eating infection of the genital and perineal area. It often requires emergency surgery, multiple debridement procedures, skin grafts, and sometimes permanent disfigurement.

Settlement amounts in pharmaceutical mass torts tend to reflect medical bills, lost income, and pain and suffering. The more invasive the treatment, the higher the potential recovery.

Think of it this way: a patient who spent weeks in the ICU and needed reconstructive surgery has a fundamentally different case than someone who caught the infection early. The compensation should match the damage.

Cases with strong medical records linking SGLT2 drug use directly to the onset of Fournier’s gangrene typically command the highest values.

Fournier’s Gangrene Settlement Amounts in 2026

Fournier’s gangrene settlement amounts in 2026 are expected to take shape as litigation moves toward potential bellwether trials and global settlement talks. No final settlements have been publicly announced as of early 2026, but projections are based on comparable pharmaceutical liability cases.

Several factors are pushing 2026 toward being a pivotal year for these claims. Courts have been consolidating cases, discovery has progressed, and both sides are beginning to assess the strength of pending claims.

• Bellwether trials could set benchmark values if they proceed in 2026
• Settlement negotiations may accelerate once early trial outcomes emerge
• Individual case values will depend on documented medical harm

Legal experts watching the SGLT2 litigation space expect that once a few cases go to verdict or settle publicly, a clearer picture of average payouts will emerge. Until then, the estimated ranges are drawn from similar drug injury cases involving necrotizing infections and surgical complications.

One important point: settlements in mass torts are almost always confidential. That means even when payments happen, specific dollar amounts rarely become public. The ranges cited here come from attorney projections and comparable case outcomes.

Quick Fact: The largest pharmaceutical injury settlements in the U.S. have historically ranged from hundreds of thousands to tens of millions per plaintiff, depending on the drug and the harm involved.

What Is the Average Settlement for Fournier’s Gangrene?

The average settlement for Fournier’s gangrene cases is projected to fall between $250,000 and $750,000 based on current litigation trends and attorney estimates. That said, no “average” truly exists yet because mass settlement payouts have not been finalized.

Averages can be misleading in pharmaceutical litigation. A handful of severe cases worth $2 million or more can pull the number up, while early-resolved claims with less documentation can drag it down.

What matters more than the average is your individual case value. That number depends on:

• Total medical expenses (past and future)
• Number and type of surgical procedures
• Duration of hospitalization
• Whether the infection caused permanent damage
• Lost wages and reduced earning capacity
• Pain, suffering, and emotional distress

If your case involves ongoing medical treatment, the value increases significantly. Fournier’s gangrene survivors often face years of follow-up care, including wound management and psychological counseling.

The “average” will become clearer once either bellwether verdicts set a benchmark or a global settlement structure is finalized. For now, treat any specific number as an estimate, not a guarantee.

Key Takeaway: Settlement amounts range from $100,000 to $2 million or more, with the average projected around $250,000 to $750,000 based on injury severity and case strength.

Fournier’s Gangrene Lawsuit Payout Per Person

The payout per person in a Fournier’s gangrene lawsuit depends entirely on the individual facts of each case. There is no flat-rate payment. Every claimant’s compensation is calculated separately.

In mass tort litigation, payouts work differently than class action settlements. You’re not splitting one pot of money with thousands of people. Instead, each plaintiff’s case is evaluated on its own merits.

Here’s what drives the per-person payout:

One person might receive $150,000 while another with the same drug but a much worse outcome could receive $1.5 million. That’s normal in this type of litigation.

Attorney fees typically run between 33% and 40% of the total recovery on a contingency basis. That means your take-home payout will be the settlement minus legal fees and case costs.

Fournier’s Gangrene Compensation Amounts Explained

Compensation in Fournier’s gangrene cases covers three main categories: economic damages, non-economic damages, and in some situations, punitive damages. Each one plays a different role in the total dollar figure.

Economic damages are the easiest to calculate. These include:

• Hospital bills and surgical costs
• Prescription medication expenses
• Follow-up care and rehabilitation
• Lost wages during recovery
• Future medical expenses for ongoing treatment

Non-economic damages are harder to pin down but often make up the largest share. They cover pain and suffering, emotional distress, loss of enjoyment of life, and disfigurement.

Punitive damages are the wild card. Courts award these when a drug manufacturer acted with reckless disregard for patient safety. If a jury finds that a company knew about the Fournier’s gangrene risk and deliberately hid it, punitive damages can multiply the total award dramatically.

Here’s the real-world comparison: it’s like totaling a car versus having a fender-bender. Insurance pays based on the actual damage. Lawsuit compensation works the same way. The worse the harm, the bigger the check.

Fournier’s Gangrene Lawsuit Update for 2026

The Fournier’s gangrene lawsuit landscape in 2026 is active, with cases continuing to move through federal and state courts. Litigation against SGLT2 inhibitor manufacturers remains ongoing, and several key developments are expected this year.

As of early 2026, here’s where things stand:

• Invokana MDL (MDL No. 2750) in the District of New Jersey continues to be the primary federal consolidation for canagliflozin claims, including Fournier’s gangrene cases
• Farxiga and Jardiance cases are being filed in various state and federal courts
• Discovery is progressing, with internal company documents under review
• Settlement negotiations are believed to be in preliminary stages for certain claim categories

The pace of pharmaceutical litigation is slow by design. Drug companies have every incentive to delay. But 2026 could bring real movement if bellwether cases are selected and trial dates are set.

Quick Fact: The FDA’s August 2018 safety communication required all SGLT2 inhibitor labels to include warnings about Fournier’s gangrene. This communication is a central piece of evidence in nearly every lawsuit.

Plaintiffs argue that manufacturers knew about the risk before 2018 and failed to act quickly enough. That timeline gap is where most claims find their legal footing.

Key Takeaway: The litigation is active in 2026, with the Invokana MDL leading the way and settlement talks potentially heating up as trial preparation advances.

SGLT2 Inhibitor Lawsuit Settlement Overview

SGLT2 inhibitor lawsuits are pharmaceutical product liability cases filed against the makers of a class of type 2 diabetes drugs. These lawsuits allege that the drugs caused serious side effects, including Fournier’s gangrene, without adequate warning.

The SGLT2 (sodium-glucose co-transporter 2) drug class includes several brand-name medications:

These drugs work by forcing the kidneys to excrete excess sugar through urine. That mechanism creates a sugar-rich environment in the urinary and genital areas, which can promote severe bacterial infections.

The core legal theory is simple: manufacturers had data showing this risk, the FDA eventually forced label changes, and patients were harmed in the gap between when the companies knew and when they warned.

Settlements in SGLT2 litigation are expected to be drug-specific, meaning claims against one manufacturer may resolve on a different timeline than claims against another. Invokana has the most litigation activity due to its earlier market entry and the volume of reported adverse events.

What Is the Fournier’s Gangrene Lawsuit About?

The Fournier’s gangrene lawsuit is about holding drug manufacturers accountable for a dangerous side effect they allegedly failed to warn patients about. Plaintiffs claim that SGLT2 inhibitor diabetes drugs caused them to develop Fournier’s gangrene, a rapidly spreading and potentially fatal infection of the genital and perineal tissues.

Here’s the sequence of events that forms the backbone of these cases:

• SGLT2 inhibitors entered the market starting in 2013 (Invokana was first)
• Patients and doctors reported cases of Fournier’s gangrene to the FDA
• The FDA identified 55 confirmed cases between March 2013 and January 2019
• In August 2018, the FDA issued a safety communication and required label updates
• Lawsuits began filing shortly after, alleging failure to warn

The legal argument centers on the concept of “failure to warn.” Plaintiffs say drug companies had enough data to recognize the Fournier’s gangrene risk earlier but chose not to update their warning labels or inform prescribing physicians.

This isn’t about a minor side effect like a headache or mild nausea. Fournier’s gangrene requires emergency hospitalization. Patients undergo painful surgical removal of dead tissue. Some lose significant portions of genital tissue. Some die.

That level of harm, combined with evidence that manufacturers delayed warnings, gives these cases real legal weight.

Who Qualifies for a Fournier’s Gangrene Lawsuit?

You may qualify for a Fournier’s gangrene lawsuit if you took an SGLT2 inhibitor diabetes drug and later developed Fournier’s gangrene. The connection between your medication use and the onset of infection is the single most important factor.

Basic qualification criteria include:

• You were prescribed an SGLT2 inhibitor (Invokana, Farxiga, Jardiance, or Steglatro)
• You developed Fournier’s gangrene while taking the drug or shortly after stopping
• You have medical records documenting both the medication and the diagnosis
• Your case falls within your state’s statute of limitations

Family members of someone who died from Fournier’s gangrene linked to an SGLT2 drug may qualify for a wrongful death claim.

One common question is whether you need proof that the drug specifically caused the infection. In practice, your medical timeline does the heavy lifting. If you were taking the drug when the infection started and had no other obvious cause, that’s typically enough to move forward.

Key Takeaway: Qualification centers on proving you took an SGLT2 drug and developed Fournier’s gangrene, with medical records and treatment history serving as the strongest evidence.

Here's something related: Clinique Advertising Dispute Model Lawsuit 2026 Updates

Fournier’s Gangrene Drug Lawsuit Eligibility Criteria

Eligibility for a Fournier’s gangrene drug lawsuit requires meeting specific medical and legal thresholds. Not everyone who took an SGLT2 inhibitor qualifies. The condition itself must be documented.

Here are the detailed eligibility criteria attorneys typically evaluate:

• Prescription verification: You must have a verifiable prescription for an SGLT2 inhibitor. Pharmacy records, insurance claims, or medical charts can provide this.
• Diagnosis confirmation: A medical professional must have diagnosed you with Fournier’s gangrene. Hospital records, surgical reports, or pathology results confirm this.
• Temporal connection: The infection must have developed during or shortly after your use of the medication. A gap of years between stopping the drug and developing the condition weakens the claim.
• No pre-existing cause: If you had a pre-existing condition that independently explains the infection (such as a traumatic injury to the area), it could complicate your claim.

Statute of limitations deadlines vary by state. Most states allow two to three years from the date of diagnosis or the date you discovered the link between your drug and the infection.

Some states apply a “discovery rule,” meaning the clock starts when you reasonably should have known the drug caused your condition. That’s an important distinction for people who weren’t aware of the connection until recently.

If you’re unsure about your eligibility, the best step is to gather your medical records and prescription history before reaching out to an attorney.

How to File a Fournier’s Gangrene Lawsuit

Filing a Fournier’s gangrene lawsuit starts with gathering your medical records and connecting with a law firm experienced in pharmaceutical mass torts. The process is more straightforward than most people expect.

Step-by-step filing process:

1. Collect your medical records. Get hospital discharge summaries, surgical reports, pathology results, and any records showing your Fournier’s gangrene diagnosis and treatment.
2. Gather prescription history. Obtain pharmacy records or insurance statements showing your SGLT2 inhibitor prescription, dosage, and duration of use.
3. Contact a mass tort attorney. Look for firms with specific experience in SGLT2 inhibitor litigation or pharmaceutical product liability cases.
4. Case evaluation. Your attorney will review your records, assess the strength of your claim, and determine estimated case value.
5. File the complaint. Your lawyer files a formal legal complaint against the drug manufacturer. This may be in federal court (joining the MDL) or in state court.
6. Discovery and litigation. Both sides exchange evidence. Your case progresses through the legal system.

Most Fournier’s gangrene cases are handled on a contingency fee basis. That means you pay nothing upfront. Your attorney only gets paid if you receive a settlement or verdict.

The entire filing process usually takes a few weeks. The litigation itself takes longer, but getting your case into the system is the critical first move.

How SGLT2 Drugs Cause Fournier’s Gangrene

SGLT2 inhibitors cause Fournier’s gangrene by creating conditions in the body that favor dangerous bacterial growth in the genital and urinary areas. The mechanism is directly tied to how these drugs lower blood sugar.

Here’s the science in plain terms. SGLT2 drugs work by blocking a protein in the kidneys that normally reabsorbs sugar back into the blood. Instead, the sugar gets flushed out through urine.

That means your urine contains significantly more sugar than normal. The warm, moist environment of the genital region combined with sugar-rich urine becomes a breeding ground for aggressive bacteria.

The infection chain looks like this:

• Sugar-rich urine creates ideal conditions for bacterial growth
• Bacteria enter through small cuts, abrasions, or urinary tract openings
• Infection spreads rapidly through soft tissue
• Tissue begins to die (necrosis)
• Without emergency treatment, the infection can become fatal

Fournier’s gangrene is a type of necrotizing fasciitis. It’s not a simple skin infection. The bacteria destroy tissue at alarming speed, sometimes spreading inches per hour.

Think of it like pouring fertilizer on weeds in a garden. The sugar acts as fuel for bacteria that are normally kept in check by the body’s defenses. SGLT2 drugs tip the balance in the bacteria’s favor.

The FDA identified this connection after reviewing adverse event reports and published case studies. By 2018, the evidence was strong enough to require a label warning on all SGLT2 inhibitor medications.

Key Takeaway: SGLT2 drugs create a sugar-rich environment in the genital area, which promotes the rapid bacterial infections that lead to Fournier’s gangrene.

Invokana Fournier’s Gangrene Lawsuit

Invokana, made by Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), faces the most Fournier’s gangrene lawsuits of any SGLT2 inhibitor. As the first drug in this class to hit the U.S. market in March 2013, it has the longest track record and the highest volume of reported adverse events.

Key facts about Invokana litigation:

The Invokana MDL was established in December 2016 and initially focused on claims related to kidney injuries, diabetic ketoacidosis, and amputations. Fournier’s gangrene claims were later added to the litigation.

Invokana generated the highest early sales volume among SGLT2 drugs. That broader patient exposure translated into more adverse event reports and more lawsuits.

Plaintiffs in Invokana cases argue that Johnson & Johnson had access to clinical trial data and post-market surveillance information showing elevated infection risks. They contend the company prioritized sales over patient safety by delaying label updates.

Several Invokana cases involving other injuries have already gone to trial or settled. These outcomes provide a reference point for estimating Fournier’s gangrene settlement values within the same MDL.

Farxiga Fournier’s Gangrene Settlement

Farxiga, manufactured by AstraZeneca, is another SGLT2 inhibitor linked to Fournier’s gangrene claims. The drug received FDA approval in January 2014 and has been prescribed to millions of type 2 diabetes patients worldwide.

Farxiga Fournier’s gangrene settlements have not been publicly finalized as of early 2026. However, cases are actively moving through the legal system, and plaintiffs are building claims based on the same failure-to-warn theory used against other SGLT2 manufacturers.

Farxiga case details:

AstraZeneca has faced scrutiny over its handling of safety signals. Internal documents showing what the company knew about genital infection risks before the FDA’s 2018 warning are expected to play a significant role in litigation.

Farxiga’s case volume is smaller than Invokana’s but growing. As awareness of the Fournier’s gangrene connection increases, more former Farxiga patients are coming forward with claims.

Settlement projections for Farxiga cases mirror the general SGLT2 ranges, with individual payouts expected between $100,000 and $2 million depending on injury severity.

Jardiance Fournier’s Gangrene Lawsuit

Jardiance, jointly marketed by Boehringer Ingelheim and Eli Lilly, is the third major SGLT2 inhibitor facing Fournier’s gangrene lawsuits. Approved in August 2014, Jardiance became one of the most widely prescribed diabetes drugs in its class.

Jardiance lawsuits follow the same legal framework as other SGLT2 cases. Plaintiffs allege that Boehringer Ingelheim and Eli Lilly knew or should have known about the Fournier’s gangrene risk and failed to provide adequate warnings to patients and doctors.

Jardiance case details:

What makes Jardiance cases interesting is the drug’s dual manufacturer structure. Both Boehringer Ingelheim and Eli Lilly share responsibility for the drug’s marketing and safety communications. That means both companies are named as defendants.

Jardiance also received FDA approval for reducing cardiovascular death risk in type 2 diabetes patients, which expanded its use significantly. More patients meant more potential exposure to the Fournier’s gangrene risk.

Settlement values for Jardiance cases are expected to align with the broader SGLT2 litigation range, with higher payouts for patients who suffered severe or permanent injuries.

Key Takeaway: All three major SGLT2 drugs (Invokana, Farxiga, and Jardiance) face active Fournier’s gangrene lawsuits, with Invokana leading in case volume and Jardiance growing steadily.

SGLT2 Inhibitor Side Effects and Lawsuits

SGLT2 inhibitor side effects extend well beyond Fournier’s gangrene, and lawsuits have been filed over multiple serious adverse reactions. Understanding the full range of side effects helps explain why litigation against these drug makers is so extensive.

Documented SGLT2 inhibitor side effects include:

Don't miss this — Lebanon CT Budget Shortfall Lawsuit 2026: What You Need

• Fournier’s gangrene (necrotizing fasciitis of the genitals)
• Diabetic ketoacidosis (dangerous acid buildup in the blood)
• Acute kidney injury
• Urinary tract infections
• Yeast infections
• Bone fractures (particularly with Invokana)
• Lower limb amputations (particularly with Invokana)
• Dehydration and low blood pressure

The FDA has issued multiple safety communications about SGLT2 inhibitors since their initial approval. The 2018 Fournier’s gangrene warning was one of several, following earlier alerts about ketoacidosis in 2015 and amputations in 2017.

Each side effect has generated its own track of lawsuits. Some have progressed further than others. The amputation cases against Invokana, for example, have already produced trial verdicts and settlements that inform projections for Fournier’s gangrene claims.

When you look at the full picture, it becomes clear why these drugs have attracted so much legal attention. The side effects aren’t minor inconveniences. They’re severe, sometimes permanent, and in some cases, fatal.

Fournier’s Gangrene Wrongful Death Lawsuit

A Fournier’s gangrene wrongful death lawsuit is filed when a patient dies as a result of the infection after taking an SGLT2 inhibitor. These cases carry the highest potential settlement values and involve surviving family members as plaintiffs.

Fournier’s gangrene has a mortality rate estimated between 20% and 40% in severe cases. When the infection progresses to sepsis or multi-organ failure, death can occur even with aggressive medical treatment.

Who can file a wrongful death claim:

• Spouse or domestic partner of the deceased
• Children (adult or minor) of the deceased
• Parents of the deceased (in some states)
• Estate representatives or personal representatives

Wrongful death claims add several damage categories not available in injury cases. These include loss of financial support, loss of companionship, funeral and burial costs, and the pain and suffering the deceased experienced before death.

The emotional weight of these cases often resonates strongly with juries. If a case goes to trial, wrongful death claims tend to produce the largest verdicts in pharmaceutical litigation.

If a loved one died from Fournier’s gangrene after taking an SGLT2 drug, the statute of limitations clock is running. Acting sooner rather than later preserves your ability to file.

Fournier’s Gangrene MDL Update

The Fournier’s gangrene MDL (multidistrict litigation) continues in 2026 under the broader umbrella of SGLT2 inhibitor federal litigation. The primary MDL for Invokana-related claims is MDL No. 2750, centralized in the U.S. District Court for the District of New Jersey.

What is an MDL? Multidistrict litigation is a federal procedure that consolidates similar lawsuits from across the country into one court for pretrial proceedings. It’s not a class action. Each plaintiff keeps their individual case, but all cases share the same discovery process, expert witness evaluations, and pretrial rulings.

2026 MDL developments to watch:

• Selection of bellwether cases specific to Fournier’s gangrene claims
• Completion of expert discovery on the SGLT2/Fournier’s gangrene causal link
• Possible Daubert hearings to determine admissibility of scientific evidence
• Settlement negotiation progress between plaintiff leadership and defendant corporations
• Potential trial dates for the first Fournier’s gangrene bellwether cases

Bellwether trials are the most important event to watch. These are test cases selected to represent the broader pool of claims. Their outcomes, whether verdict or settlement, typically set the benchmark for resolving remaining cases.

Think of bellwether trials like test flights before a commercial airline launch. They show both sides what a full trial looks like and what juries are willing to award. That information usually pushes both parties toward a global settlement.

If you have a pending claim, the MDL timeline directly affects when you might receive compensation. Most mass tort resolutions happen after bellwether outcomes are known.

Key Takeaway: The Fournier’s gangrene MDL is active in 2026, with bellwether trial selection and potential settlement negotiations representing the most significant upcoming milestones.

Frequently Asked Questions

How much is the average Fournier’s gangrene lawsuit settlement in 2026?

The average settlement is projected between $250,000 and $750,000 based on attorney estimates and comparable pharmaceutical cases.

Exact amounts depend on your injury severity, medical costs, and the strength of your documentation.

No final mass settlement has been publicly announced as of early 2026.

Which diabetes drugs are linked to Fournier’s gangrene lawsuits?

Four SGLT2 inhibitor drugs are linked: Invokana, Farxiga, Jardiance, and Steglatro.

All four were subject to the FDA’s August 2018 safety warning requiring updated labels.

Combination drugs containing these active ingredients are included as well.

Can I still file a Fournier’s gangrene lawsuit in 2026?

Yes, you can still file in 2026 if your claim falls within your state’s statute of limitations.

Most states allow two to three years from the date of diagnosis or discovery of the drug connection.

Contact an attorney immediately to verify your specific deadline.

How long does a Fournier’s gangrene lawsuit take to settle?

Most pharmaceutical mass tort cases take three to five years from initial filing to settlement payout.

Cases filed in 2023 or 2024 could see resolution in 2026 or 2027 if bellwether trials proceed on schedule.

Individual timelines vary based on case complexity and court schedules.

What evidence do I need for a Fournier’s gangrene claim?

You need medical records confirming your Fournier’s gangrene diagnosis, prescription records showing SGLT2 inhibitor use, and documentation of your treatment and expenses.

Hospital discharge summaries, surgical reports, and pharmacy records are the most critical documents.

Stronger documentation typically leads to higher settlement offers.

What to Do Right Now

The window to file a Fournier’s gangrene lawsuit in 2026 is open, but statutes of limitations are ticking for many potential claimants. If you took an SGLT2 drug and developed this condition, your next step is to gather your medical and prescription records.

Settlement amounts in these cases are substantial because the injuries are severe. Don’t wait for a public settlement announcement to start the process.

Get your records together. Talk to a qualified mass tort attorney. Make sure your claim is filed before your state’s deadline passes.

You may want to read Startups Lawsuit 2026: Eligibility, Payouts and Deadlines

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.